Nuchev (ASX:NUC), an Australian-based nutritional and wellness business, has released its Annual Report for FY26, disclosing group revenue of $25.7 million, a statutory loss after tax of $7.4 million, and cash of $2.1 million at 30 June 2026.
Key Points
- Group revenue increased by 12% to $25.7 million in FY26
- Gross profit increased by 3.2% to $11.2 million, while gross margin reduced from 47.3% to 43.6%
- Adjusted EBITDA loss of $4.6 million, compared with a loss of $3.3 million in FY25
- Statutory loss after tax of $7.4 million, including a $1.9 million non-cash impairment of goodwill associated with the Practitioner business
- Net cash used in operating activities was $6.6 million, with cash of $2.1 million at 30 June 2026
FY26 Financial Results Overview
Nuchev's FY26 Annual Report discloses group revenue of $25.7 million, representing a 12% increase on the prior period. Gross profit rose 3.2% to $11.2 million, however gross margin contracted from 47.3% to 43.6%, which the filing attributes to changes in product and channel mix and distribution becoming a larger part of the business. The adjusted EBITDA loss widened to $4.6 million from $3.3 million in FY25. The statutory loss after tax of $7.4 million included a $1.9 million non-cash impairment of goodwill associated with the Practitioner business. Net cash used in operating activities was $6.6 million, with the company holding cash of $2.1 million at 30 June 2026.
Brauer Distribution and Oli6® Functional Foods Expansion
According to the filing, Nuchev's Oli6® brand continued to perform domestically during FY26, while Brauer began making a more meaningful contribution following the company's move to a full distribution model in March 2026. The company also expanded the Oli6® range into functional foods during the period and launched new digital platforms, building more direct routes to consumers, practitioners and retail customers. Nuchev's portfolio spans infant formula and adult nutrition, practitioner-only therapeutics and retail pharmacy, with brands including Oli6®, BioPractica, Medicine Tree, and globally recognised European brands sold under exclusive licence in Australia and New Zealand through bWellness.
Business Operations and Strategic Focus
The filing states that Nuchev operates across Australia, New Zealand, China and Vietnam, partnering with manufacturers, distributors and retailers. The company's stated focus is on stabilising the Oli6® export market, new brand launches and an improved Practitioner business. The filing describes working-capital management as a core part of the company's strategy, noting that strong demand planning and inventory management will be important as the portfolio grows. Nuchev's CEO is Nathan Cheong, and the company is headquartered on the traditional lands of the Wurundjeri Woi Wurrung peoples in Victoria. The company's stated vision is to lead globally as a House of Brands transforming wellness, longevity and quality of life through therapeutic, future-focused solutions.




Please wait processing your request...